Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Lafita, Y. Sáez, J.P. Sáez de la Fuente, I. Narváez, E. Baztán, A. Magro, et al.
Determinación de apolipoproteínas B y A-I en sangre desecada en tarjeta: estudio preliminar.
Clin Invest Arterioscler, 15 (2003), pp. 133-139
[2.]
J.J. Maciejko, D.R. Homes, B.A. Kottke, A.R. Zinsmeister, D.M. Dinh, S.T.T. Mao.
Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease.
N Engl J Med, 309 (1983), pp. 385-389
[3.]
S.R. Srinivasan, G.S. Berenson.
Apolipoproteins B and A-I as predictors of risk of coronary artery disease.
Lancet, 358 (2001), pp. 2012-2013
[4.]
G. Walldius, I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, E. Steiner.
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.
Lancet, 358 (2001), pp. 2026-2033
[5.]
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
[6.]
A.D. Sniderman, J. Ribalta, M. Castro Cabezas.
How should FCHL be defined and how should we think about its metabolic bases?.
Nutr Metab Cardiovasc Dis, 11 (2001), pp. 259-273
[7.]
A.D. Sniderman, M. Castro Cabezas, J. Ribalta, R. Carmena, T.W.A. De Bruin, J. De Graaf, et al.
A proposal to redefine familial combined hyperlipidemia — Third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical Investigation.
Eur J Clin Invest, 32 (2002), pp. 71-73
[8.]
A.D. Sniderman, G.R. Dagenais, B. Cantin, J.P. Desprès, B. Lamarche.
High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol.
Am J Cardiol, 87 (2001), pp. 792-793
[9.]
J. Rubiés-Prat, J.L. Reverter, M. Sentí, J. Pedro-Botet, I. Salinas, A. Lucas, et al.
Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus.
Diabetes Care, 16 (1993), pp. 1081-1086
[10.]
S. Iraní, D. Li, I. Jialal.
A more valid measurement of low-density lipoprotein cholesterol in diabetic patients.
Am J Med, 102 (1997), pp. 48-53
[11.]
A.M. Wagner, J.L. Sánchez-Quesada, A. Pérez, M. Rigla, M. Cortés, F. Blanco-Vaca, et al.
Inaccuracy of calculated LDL-cholesterol in type 2 diabetes: consequences for patient risk classification and therapeutic decisions.
Clin Chem, 46 (2000), pp. 1830-1832
[12.]
A.M. Wagner, A. Pérez, F. Calvo, R. Bonet, A. Castellví, J. Ordóñez.
Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.
Diabetes Care, 22 (1999), pp. 812-817
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.